Back to top
more

Amgen (AMGN)

(Real Time Quote from BATS)

$304.33 USD

304.33
371,185

+4.03 (1.34%)

Updated May 8, 2024 10:38 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (90 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva

Top Ranked Income Stocks to Buy for August 14th

by Zacks Equity Research

Here are four stocks with buy rank and strong income characteristics for investors to consider today, August 14th.

Here's Why Amgen Stock is Outperforming Its Industry Of Late

by Zacks Equity Research

Favorable patent ruling related to Enbrel and strong second-quarter results drive Amgen (AMGN) stock 22.6% higher in the past three months.

Should Value Investors Choose Amgen (AMGN) Stock Now?

by Zacks Equity Research

Let's see if Amgen (AMGN) stock is a good choice for value-oriented investors right now from multiple angles.

Is Amgen (AMGN) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (AMGN) Outperforming Other Medical Stocks This Year?

Will Amgen Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor Amgen.

Mergers & Acquisitions Take Center Stage in Biotech Industry

by Zacks Equity Research

Mergers & acquisitions are in focus in the biotech industry as it undergoes a wave of consolidation.

Amgen Wins Enbrel U.S. Patent Litigation Against Novartis

by Zacks Equity Research

Despite lower demand hurting volumes of Enbrel, it remains the largest drug for Amgen (AMGN). A district court decision prevents Novartis from launching Erelzi, its biosimilar version of Enbrel.

Company News For Aug 12, 2019

by Zacks Equity Research

Companies In The News Are: UBER,AMGN,NWSA,DXC

Top Ranked Income Stocks to Buy for August 12th

by Zacks Equity Research

Here are four stocks with buy rank and strong income characteristics for investors to consider today, August 12th.

Kalyan Nandy headshot

Top Analyst Reports: Amgen, Uber, Mondelez & More

by Kalyan Nandy

Today's Research Daily features updated research reports on 16 major stocks, including Amgen (AMGN), Uber (UBER) and Mondelez (MDLZ).

Puma (PBYI) Q2 Earnings Miss, Nerlynx Sales Rise, Stock Up

by Zacks Equity Research

Puma Biotech (PBYI) incurs wider loss in Q2. Sales of Nerlynx improve from first-quarter levels. Stock rises 23%.

Radius (RDUS) Q2 Earnings Beat Estimates, Tymlos Sales Solid

by Zacks Equity Research

Radius (RDUS) reports a narrower-then-expected loss and beats sales estimates in the second quarter of 2019.

Intercept (ICPT) Q2 Earnings & Sales Beat, NASH in Focus

by Zacks Equity Research

Intercept (ICPT) posts a narrower-than-expected loss in Q2 and surpasses sales estimates.

Teva (TEVA) Q2 Earnings, Sales Top Estimates, CFO Steps Down

by Zacks Equity Research

Teva Pharmaceutical (TEVA) posts better-than-expected results. However, earnings and sales decline year over year.

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

by Zacks Equity Research

Sector ETF report for PBE

Sweta Jaiswal, FRM headshot

Biotech ETFs in Focus on Impressive Q2 Earnings Results

by Sweta Jaiswal, FRM

Let's take a look at some ETFs with wide exposure to a few biotechnological companies which released solid Q2 earnings results recently.

Allergan (AGN) Q2 Earnings & Sales Top, '19 Sales View Up

by Zacks Equity Research

Botox, Juvederm fillers, Vraylar and Ozurdex drive Allergan's (AGN) second-quarter sales, making up for loss of exclusivity on some brands and lower sales of Restasis and textured breast implants.

Is Amgen (AMGN) a Great Value Stock Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Biotech Stock Roundup: Celgene, Amgen, Gilead Impress in Q2, Other Pipeline Updates

by Zacks Equity Research

Impressive second-quarter results by most biotech bigwigs are the key highlights of the week. Most companies also increase their annual guidance.

Ligand (LGND) Stock Down Despite Q2 Earnings & Sales Beat

by Zacks Equity Research

Ligand (LGND) reports better-than-expected second-quarter 2019 results and maintains view for the full year.

Amgen (AMGN) Q2 Earnings & Sales Beat, New Drugs Shine

by Zacks Equity Research

Amgen (AMGN) beats estimates for earnings and sales in the second quarter. Higher demand for new growth drivers was offset by the erosion of mature brands from brand/biosimilar competition.

Amgen (AMGN) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Amgen (AMGN) delivered earnings and revenue surprises of 10.89% and 3.43%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Lilly (LLY) Q2 Earnings Beat, New Drugs Drive Sales, Stock Up

by Zacks Equity Research

Eli Lilly's (LLY) Q2 earnings beat estimates while sales miss. New drugs drive sales despite generic competition to key drug Cialis.

Sanofi (SNY) Q2 Earnings Top, Dupixent Shines, EPS View Up

by Zacks Equity Research

Sanofi (SNY) beats estimates for second-quarter earnings. Key immunology drug Dupixent drives sales. The company ups its earnings growth expectations for the year.

Why Amgen (AMGN) Might Surprise This Earnings Season

by Zacks Equity Research

Amgen (AMGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.